Joshua Sharfstein has his marching orders--from Dr. Marcia Angell, former New England Journal of Medicine editor-in-chief and current Harvard Medical School lecturer. In a Washington Post column, Angell set out a list of seven goals for Sharfstein, who's acting commissioner of the FDA while Margaret Hamburg awaits Senate confirmation as permanent chief, and his future boss.
Now, Angell has a particular point of view; she's published a book called The Truth About the Drug Companies: How They Deceive Us and What to Do About It. But that doesn't mean her recommendations should automatically be pooh-poohed by pharma as, well, anti-pharma. Several of her ideas have been advanced by plenty of not-so-anti-pharma folk. And all of them have been bandied about in recent months by one expert or another. But enough preamble; here they are, for your critique.
So, what do you think? Any additions or subtractions? Any of these recommendations patently unfair or potentially ruinous? Or do you love them all?
- read the Post column [1]
Related Articles:
FDA needs overhaul, but what to do? [2]
Pharma types 'nervous' about Sharfstein [3]
Hamburg chosen as FDA chief, Sharfstein as deputy [4]
Obama FDA picks raise some hackles [5]
Links:
[1] http://www.boston.com/bostonglobe/editorial_opinion/oped/articles/2009/04/06/charting_a_new_course_at_the_fda/
[2] http://www.fiercepharma.com/story/fda-needs-overhaul-what-do/2009-03-04
[3] http://www.fiercepharma.com/story/pharma-types-nervous-about-sharfstein/2009-03-20
[4] http://www.fiercebiotech.com/story/obama-taps-hamburg-fda-agency-critic-deputy/2009-03-12
[5] http://www.fiercepharma.com/story/obama-fda-picks-raise-some-hackles/2009-03-16